Financhill
Sell
34

IOBT Quote, Financials, Valuation and Earnings

Last price:
$0.96
Seasonality move :
-14.35%
Day range:
$0.90 - $0.96
52-week range:
$0.66 - $1.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.32x
Volume:
62.5K
Avg. volume:
207K
1-year change:
-36.58%
Market cap:
$62.3M
Revenue:
--
EPS (TTM):
-$1.37

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IOBT
IO Biotech
-- -$0.23 -- -23.33% $9.00
NBY
NovaBay Pharmaceuticals
$3M -$0.24 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
PTN
Palatin Technologies
-- -$0.17 -- -67.93% --
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% $6.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IOBT
IO Biotech
$0.95 $9.00 $62.3M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.59 $0.85 $3.4M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.34 -- $21M -- $0.00 0% --
OGEN
Oragenics
$0.19 $1.00 $4.1M -- $0.00 0% 1.20x
PTN
Palatin Technologies
$0.21 -- $5.3M -- $0.00 0% --
TOVX
Theriva Biologics
$1.41 $6.00 $3.9M -- $0.00 0% 0.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IOBT
IO Biotech
-- -2.267 -- --
NBY
NovaBay Pharmaceuticals
4.54% 0.451 1.51% 0.75x
NNVC
Nanoviricides
-- 1.928 -- --
OGEN
Oragenics
-- 3.461 -- --
PTN
Palatin Technologies
-- 0.220 -- --
TOVX
Theriva Biologics
-- -1.635 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IOBT
IO Biotech
-- -$26.5M -- -- -- -$20.8M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
NNVC
Nanoviricides
-- -$2.1M -- -- -- -$2.2M
OGEN
Oragenics
-- -$3.4M -- -- -- -$2M
PTN
Palatin Technologies
-- -- -- -- -- --
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M

IO Biotech vs. Competitors

  • Which has Higher Returns IOBT or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to IO Biotech's net margin of -49.65%. IO Biotech's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    IOBT
    IO Biotech
    -- -$0.36 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About IOBT or NBY?

    IO Biotech has a consensus price target of $9.00, signalling upside risk potential of 852.38%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 45.3%. Given that IO Biotech has higher upside potential than NovaBay Pharmaceuticals, analysts believe IO Biotech is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    IOBT
    IO Biotech
    2 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is IOBT or NBY More Risky?

    IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

  • Which is a Better Dividend Stock IOBT or NBY?

    IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IOBT or NBY?

    IO Biotech quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IO Biotech's net income of -$24M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, IO Biotech's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IOBT
    IO Biotech
    -- -- -- -$24M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M -$1.2M
  • Which has Higher Returns IOBT or NNVC?

    Nanoviricides has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IOBT
    IO Biotech
    -- -$0.36 --
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About IOBT or NNVC?

    IO Biotech has a consensus price target of $9.00, signalling upside risk potential of 852.38%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 385.08%. Given that IO Biotech has higher upside potential than Nanoviricides, analysts believe IO Biotech is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    IOBT
    IO Biotech
    2 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is IOBT or NNVC More Risky?

    IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.927, suggesting its less volatile than the S&P 500 by 7.287%.

  • Which is a Better Dividend Stock IOBT or NNVC?

    IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IOBT or NNVC?

    IO Biotech quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. IO Biotech's net income of -$24M is lower than Nanoviricides's net income of -$2M. Notably, IO Biotech's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IOBT
    IO Biotech
    -- -- -- -$24M
    NNVC
    Nanoviricides
    -- -- -- -$2M
  • Which has Higher Returns IOBT or OGEN?

    Oragenics has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IOBT
    IO Biotech
    -- -$0.36 --
    OGEN
    Oragenics
    -- -$0.27 --
  • What do Analysts Say About IOBT or OGEN?

    IO Biotech has a consensus price target of $9.00, signalling upside risk potential of 852.38%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that IO Biotech has higher upside potential than Oragenics, analysts believe IO Biotech is more attractive than Oragenics.

    Company Buy Ratings Hold Ratings Sell Ratings
    IOBT
    IO Biotech
    2 0 0
    OGEN
    Oragenics
    0 1 0
  • Is IOBT or OGEN More Risky?

    IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.

  • Which is a Better Dividend Stock IOBT or OGEN?

    IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IOBT or OGEN?

    IO Biotech quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. IO Biotech's net income of -$24M is lower than Oragenics's net income of -$3.3M. Notably, IO Biotech's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 1.20x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IOBT
    IO Biotech
    -- -- -- -$24M
    OGEN
    Oragenics
    1.20x -- -- -$3.3M
  • Which has Higher Returns IOBT or PTN?

    Palatin Technologies has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IOBT
    IO Biotech
    -- -$0.36 --
    PTN
    Palatin Technologies
    -- -- --
  • What do Analysts Say About IOBT or PTN?

    IO Biotech has a consensus price target of $9.00, signalling upside risk potential of 852.38%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3314.63%. Given that Palatin Technologies has higher upside potential than IO Biotech, analysts believe Palatin Technologies is more attractive than IO Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    IOBT
    IO Biotech
    2 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is IOBT or PTN More Risky?

    IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

  • Which is a Better Dividend Stock IOBT or PTN?

    IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IOBT or PTN?

    IO Biotech quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. IO Biotech's net income of -$24M is higher than Palatin Technologies's net income of --. Notably, IO Biotech's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IOBT
    IO Biotech
    -- -- -- -$24M
    PTN
    Palatin Technologies
    -- -- -- --
  • Which has Higher Returns IOBT or TOVX?

    Theriva Biologics has a net margin of -- compared to IO Biotech's net margin of --. IO Biotech's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IOBT
    IO Biotech
    -- -$0.36 --
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About IOBT or TOVX?

    IO Biotech has a consensus price target of $9.00, signalling upside risk potential of 852.38%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 324.21%. Given that IO Biotech has higher upside potential than Theriva Biologics, analysts believe IO Biotech is more attractive than Theriva Biologics.

    Company Buy Ratings Hold Ratings Sell Ratings
    IOBT
    IO Biotech
    2 0 0
    TOVX
    Theriva Biologics
    0 0 0
  • Is IOBT or TOVX More Risky?

    IO Biotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

  • Which is a Better Dividend Stock IOBT or TOVX?

    IO Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IO Biotech pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IOBT or TOVX?

    IO Biotech quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. IO Biotech's net income of -$24M is lower than Theriva Biologics's net income of -$4.4M. Notably, IO Biotech's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IO Biotech is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IOBT
    IO Biotech
    -- -- -- -$24M
    TOVX
    Theriva Biologics
    0.63x -- -- -$4.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Is Okta Stock Finally Gaining Investor Confidence?
Is Okta Stock Finally Gaining Investor Confidence?

Given how digital transformation has proliferated, cyberattacks have also been…

Is The Trade Desk the Best Advertising Stock Now?
Is The Trade Desk the Best Advertising Stock Now?

The worldly backdrop is now shrouded in heavy uncertainty and…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
55
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 37x

Alerts

Buy
85
HIMS alert for Apr 30

Hims & Hers Health [HIMS] is down 5.48% over the past day.

Buy
54
EAT alert for Apr 30

Brinker International [EAT] is down 1.82% over the past day.

Sell
16
NSP alert for Apr 30

Insperity [NSP] is down 3.3% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock